Xenetic & Tokyo Medical University Signs Aggrement for Advancing of DNase-Based Oncology Platform

Xenetic & Tokyo Medical University Signs Aggrement for Advancing of DNase-Based Oncology Platform

By, Admin 22 October 2024

Xenetic Biosciences inks materials transfer agreement with Tokyo Medical University for advancement of DNase-based oncology platform

Overview

Xenetic Biosciences, Inc., a biopharmaceutical company focused on advancing innovative immuno-oncology technologies addressing hard to treat oncology indications, announced it has entered into a Materials Transfer Agreement with Tokyo Medical University to advance the development of its systemic DNase programme.

Terms of the Agreement

  • Under the terms of the agreement, Professor Takuro Nakamura of the Department of Experimental Pathology, Institute of Medical Science at Tokyo Medical University will lead the research programme evaluating the effects of human recombinant DNase I (rhDNase I) when given in combination with chemotherapy in a proprietary immunocompetent preclinical mouse model of Ewing sarcoma. 
  • Professor Takuro Nakamura's proprietary immunocompetent Ewing sarcoma model encompasses the biological characteristics, morphology and gene expression profiles of human Ewing sarcoma and has demonstrated translational relevance.

About Ewing Sarcoma

  • Ewing sarcoma is an aggressive orphan paediatric cancer that grows in bones or soft tissues, accounting for between 2 to 3 per cent of all childhood cancers. 
  • There is a lack of effective treatment options for children with recurrent and metastatic disease where the five-year survival rate is only 20 to 30 percent for patients that have relapsed.

Clinical Studies Results (2010-2021)

  • Clinical studies conducted at Tel Aviv Medical Center between 2010 and 2021 showed that the formation of neutrophil extracellular traps (NETs) in the tumour microenvironment of Ewing sarcoma is an independent prognostic factor, with a clear association between NETs burden and poor prognosis. 
  • According to research from these clinical studies, elevated levels of NETs at diagnosis predicted a poor response to neoadjuvant chemotherapy, relapse, and death from the disease.

The Recombinant DNase I

  • Xenetic's proprietary recombinant DNase I is an enzyme that digests NETs in tumour microenvironment. 
  • The preclinical studies are designed to evaluate the efficacy of DNase to reduce NETs burden and to increase the efficacy of chemotherapy given in an adjuvant setting.

Statememt from the CEO: Xenetic Biosciences

James Parslow, interim chief executive officer and chief financial officer of the company stated, ""As part of our overall development strategy, we aim to leverage relationships like the one established with Tokyo Medical University. Our commitment to the DNase programme remains steadfast, and we are pleased to enter into this agreement to further expand our growing body of data.""

About the DNase-Based Oncology Platform

  • Xenetic's DNase-based oncology platform is designed to target NETs, which are weblike structures composed of extracellular chromatin coated with histones and other proteins. 
  • In cancer, NETs are expelled by activated neutrophils into the tumour microenvironment and blood, thereby promoting cancer spread and local and systemic immunosuppression. 
  • Reduction of NETs burden via application of Xenetic's proprietary recombinant human DNase I has been shown to improve efficacy of immunotherapy, adoptive cell therapy and chemotherapy in preclinical animal models.

Optimize Your trial insights with Clival Database.

Are you exhausted from the uncertainty of trial insights pricing? Clival Database ensures the clarity in the midst of the global scenario for clinical trials to you.

Clival Database is one of the best databases that offers an outstanding number of clinical trial data in terms of 50,000+ molecules and from primary regulatory markets as well as new entrants like Indian and Chinese markets.

With Clival, you get accurate positioning of historical sales data, patent database, company profiling, safety & efficacy, and prediction of launch of new innovative molecules helping you to align your research and driving down the cost.

To add value, we further break down our analytics for you so that improving your operational effectiveness; optimizing your clinical trials; and offering you accurate and high-quality data at lowest possible prices becomes possible.

Elevate your trial success rate with the cutting-edge insights from Clival database.

Check it out today and make more informed sourcing decisions! Learn More!